Page 1908 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

Index 1335

Cost-effectiveness ratio, 38, 42 Critical care pharmacology, 1223–1241 polyneuropathy, 106–107
Cost estimates and guesses, 42 individualization of drug therapy in rehabilitation framework—International
Cost measurement, 42 intensive care unit, Classification of Functioning,
Cost-minimization analysis, 38 1227–1241, 1227f Disability, and Health (ICF),
Costs, 40 adverse drug reactions, 1239–1241 109–110
Cost streams, 42 consideration of potential drug-drug sarcopenia of aging, 108
Cost-utility analysis, 39 interactions, 1238–1239 treatment - early mobility and
Coughing, in clearing blood from airway, 510 half-life, 1238 rehabilitation, 113–114
Coxsackievirus, 676 hepatic biotransformation, 1232, 1232t, malaria in, 716
Cranial epidural abscess, 686 1233t, 1234–1238, 1234t, management of, 711–721
C-reactive protein, 1247 1235ft, 1236t mobilization of, 163
sepsis and, 567 loading dose, 1228 pathophysiology of anemia in, 842
Cricothyroid muscle, 404 maintenance dose, 1228–1230 pathophysiology of circulation in, 228–241,
Cricothyroidotomy, 1117–1118 renal excretion, 1230–1232 229f, 230f, 231ft, 233f, 234f, 236t,
Crimean Congo hemorrhagic fever, route of drug administration, 1228 238f, 239f, 240ft, 241f
718, 740–741 therapeutic drug monitoring, 1239 pharmacokinetics and pharmacodynamics
Critical care pharmacokinetic and pharmacodynamic in, 544–545, 544f
documentation in, 129–130 principles, 1224–1227 potential adverse effects of sleep disruption
electrolyte disorder in, 943–968 bioavailability, 1224 in, 158, 158t
handling of mass casualties in, 56–57 drug distribution and elimination, red blood cell transfusion in, 843
implementing curriulum, in intensive 1224–1226, 1224f, 1225ft, 1226 rickettsial diseases, 718–719
care unit, 5, 5t pharmacodynamic modeling, 1226–1227 Rocky Mountain spotted fever, 718–719
infectious complications of intravascular renal excretion, 1230–1232 sleep in, 159–161, 159t
access devices used in, 588–593 Critical care ultrasonography, applications transportation of, 69–76
interface between end-of-life care, palliative of, 203–205 prior to transfer, 69–75, 70t, 71–72, 73t,
care and, 121 Critical illness 74ft, 75f
interpreting and applying evidence, 44–48 acute respiratory failure in, 720 special circumstances/clinical conditions,
measures of association and quantifying MERS-CoV, 720 75–76, 76t
effect size, 46 SARS, 720 thyroid hormone physiology in, 987, 987f
observational studies, 45 care of caregiver after, 114–116 tissue corticosteroid resistance during, 982
p values, confidence intervals, and power, circadian rhythmicity in, 158–159 ulcer node syndromes, 719–720
46–47 clinical assessment of bleeding in, 845, 845t plague, 719
qualitative data and its role in critical diagnostic approaches and early tularemia, 719–720
care research, 48 therapeutics, 713–716 ventricular dysfunction in, 229–233, 229f,
randomized controlled trials, 45–46 empiric therapy in the traveler, 716 230f, 231ft
surrogate outcomes measures in critical initial diagnostics, 714–715, 715f viral hemorrhagic fevers, 717–718
care research, 46 physical examination, 714, 714t dengue, 717–718
understanding diagnostic test, 47–48 supportive measures, 715–716 Ebola/Marburg, 718
legal issues in, 125–130 erythropoietin in, 844 hantavirus, 718
decisional capacity and surrogate evaluation of, with diarrhea, 706t, 707–708 Critical illness myopathy, 107, 768, 768t
decision making, 126–127 glycemic control in, 144–145 Critical illness neuromyopathy (CINM), 767
informed consent and refusal, 126 impact on public health and community, Critical illness polyneuromyopathy, 768
legal responsibility and vicarious 720–721 Critical illness polyneuropathy, 106–107,
liability, 129 importance of, 712, 712t 767–768, 767t
measuring quality of experience of, influenza in, 716–717 Critical illness-related corticosteroid
117, 118t investigating mechanisms and insufficiency, 980–986, 980f
obesity and delivery of, 1310, 1310t management of, 6–7 clinical manifestations, 982–983
organizing team in, 3 long-term outcomes after, 103–114 cortisol physiology, 980–981, 981f
psychological burden of, on patient’s additional physical morbidities, diagnosis of adrenal insufficiency, 983
relatives, 117 108–109, 109f hypothalamic-pituitary-adrenal axis failure
qualitative data and its role in, 48 barriers to construction of rehabilitative in acute illness, 982, 982t
quality indicators in, 12–15, 14t models after, 110 perioperative corticosteroids in patients
risk management in, 130 caregiver and family burden in, 113 on chronic corticosteroids,
role of, in bioterrorism, 751–752, 752t clinical phenotypes in, and spectrum of 985–986
scholarship of teaching and discovery in, disability, 107–108, 108f tissue corticosteroid resistance during, 982
5–7, 5t critical illness-associated brain injury, treatment with corticosteroids,
surging resources, 59 110–113 983–985, 984t
surrogate outcomes measures in, 46 differential repair, 108 Critical Pathway for the Organ Donor, 1108
teaching, in curricula of medical schools health-related quality of life, 104–105 Cross-clamp, 1068
and residency programs, 6 neuropsychological morbidities and, Cross-reactions, 1271
Critical care echocardiography, basic, 105–106 Cruzan, Nancy, case of, 127–128
206–207 long-term functional disability, 105, 106f Cryoglobulins, 1249, 1250
Critical Care Family Needs Inventory myopathy, 107 Cryoprecipitate, 857
(CCFNI), 117, 118t neuromuscular dysfunction, 106, 106f Cryptococcus neoformans, 638–639, 639f
Critical Care Family Satisfaction Survey, 117 phase-specific approach to recovery Crystalloid solutions, acid-base
Critical care information system (CCIS), 55 after, 110 balance and, 970

Index.indd 1335 23-01-2015 15:33:51